Health economics of nutrigenomics in weight management

Gene Therapy and Molecular Biology

Volumn 12, Issue 1, 2008, Pages 25-30

  Meshkin, Brian ^a   Chen, Thomas J H ^b   Chen, Amanda L C ^b   Prihoda, Thomas J H ^c   Morrisette, Hayley ^d   Braverman, Eric R ^d,e   Blum, Seth H ^f   Cassel, Kimberly ^f   Williams, Lonna ^g   Waite, Roger L ^g   Downs, B Williams ^g   Tung, Howard ^h   Rhoades, Patrick ⁱ   Blum, Kenneth ^d,f,g,j  

^a Salugen Inc   (United States)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d Path Medical Research Foundation   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Synaptamine Inc   (United States)

^g LifeGen Inc   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Central Valley Comprehensive Obesity Clinic   (United States)

^j WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Bioeconomics; LG839 variant; Nutrigenetics; Obesity; Reward Deficiency Syndrome (RDS)

Indexed keywords

EID: 50849130609     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ament A, Evers S (1993) Cost of illness studies in health care: a comparison of two cases. Health Policy 26, 29-42.
2. Behrens C, Henke KD (1988) Cost of illness: no aid to decision making? Health Policy 10, 137-141.
3. Behrens C, Henke KD (1988) Cost of illness: no aid to decision making? Written as a Reply to Shiell et al. Health Policy 10, 137-141.
4. Beltz SE, Yee GC (1998) Pharmacoeconomics of cancer therapy. Cancer Control 5, 415-424.
5. Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mengucci JF, Braverman ER, Arcuri V, Varshavskiy M, Deutsch R, Martinez-Pons M ( 2006) Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a LG839 variant variant. Adv Ther 23, 1040-1051.
6. Chadwick R (2004) Nutrigenomics, individualism and public health. Proc Nutr Soc 63, 161-166.
7. Costello D (2005) The personal financial cost of obesity. Los Angeles Times.
8. Dervieux T, Meshkin B, Neri B (2005) Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 573: 180-94.
9. Greenberg PE, Arcelus A, Birnbaum HG, Cremieux PY, LeLorier J, Ouellette P, Slavin MB (1999) Pharmacoeconomics and health policy. Current applications and prospects for the future. Pharmacoeconomics 16, 425-432.
10. Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G (1999) Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracyclineresistant breast cancer. J Clin Oncol 17, 3082-3090.
11. Murray CJL, Lopez AD, eds. (1994) Global comparative assessments in the health sector: disease burden, expenditure and intervention packages. Geneva: World Health Organization.
12. Rice DP (1994) Cost-of-illness studies: fact or fiction? Lancet 344, 1519-1520.
13. Thorpe KE, Florence CS, Howard DH, Joski P (2005) The Rising Prevalence Of Treated Disease: Effects On Private Health Insurance Spending. Health Aff (Millwood), Suppl Web Exclusives:W5-317-W5-325.
14. van Ginkel E, Jager S, van der Sanden W (1999) Hunebedden, monumenten van een steentijdcultuur. Uitgeverij Uniepers Abcoude.
15. Zagorsky JL (2005) Health and wealth: The late-20th century obesity epidemic in the U.S. Econ Hum Biol 3, 296-313.